Joining us now exclusively is [music] incoming Crowd Time CEO Steve Kaine. Steve, thank you so much for taking the time on this big announcement. It's good to see you. >> Good to see you, Sarah.Thanks for having me. >> So, why now. Why are you doing this.I mean, you you you you did the split at Kellogg, sold effectively both of those two companies could have could have rode off into the sunset. Why are you back for more. >> Yeah, I I could have, but this opportunity was just so exciting, Sarah.And when you ...

Financial Performance - For Q3 2025, net sales were $2.62 billion, a 13% increase compared to Q3 2024, while organic sales rose by 11% [10][14] - Year-to-date (YTD) net sales reached $13.49 billion, reflecting a 4% increase from 2024, with organic sales up 6% [5][14] - The company reported a loss from continuing operations of $308 million in Q3 2025, an improvement from a loss of $519 million in Q3 2024 [12][14] - Operating EBITDA for Q3 2025 was $49 million, a 149% increase year-over-year [12][14] Segment Performance - Crop Protection segment net sales for Q3 2025 were approximately $1.70 billion, up 4% from Q3 2024, driven by a 5% increase in volume [19][21] - Seed segment net sales were $917 million in Q3 2025, up from $691 million in Q3 2024, with a 27% increase in volume [15][21] - Crop Protection YTD net sales were approximately $5.33 billion, a 3% increase from the same period in 2024 [21][24] - Seed YTD net sales reached $8.16 billion, a 5% increase from 2024, with a 3% increase in price/mix and a 4% increase in volume [15][24] Strategic Initiatives - The company plans to separate into two independent public companies by the second half of 2026, with "New Corteva" focusing on crop protection and "SpinCo" on advanced genetics [7][8] - The separation is expected to enhance long-term value through tailored innovation and capital allocation strategies [6][13] - Full-year 2025 guidance has been raised, with net sales expected between $17.7 billion and $17.9 billion, and operating EBITDA projected between $3.8 billion and $3.9 billion [5][26] Market Outlook - The global agricultural outlook remains mixed, with strong demand but pressured commodity prices and farmer margins [25][26] - The company anticipates a large crop production year, with record demand leading to low global corn stock levels [25][26] - Global crop protection industry volumes have stabilized, with signs of price stabilization emerging [26]

Core Insights - The Kraft Heinz Company reported a decline in both top and bottom lines for Q3 2025, primarily due to weaker volumes in key categories, but management highlighted progress in productivity initiatives and brand investments [1][10] - The company is preparing for its planned separation into two standalone public companies, "Global Taste Elevation Co." and "North American Grocery Co." in the second half of 2026 [3][10] Financial Performance - Adjusted earnings were 61 cents per share, exceeding the Zacks Consensus Estimate of 57 cents, but fell 18.7% year over year due to lower adjusted operating income and increased taxes [4] - Net sales totaled $6,237 million, down 2.3% year over year, missing the Zacks Consensus Estimate of $6,247 million, with organic net sales declining 2.5% [5] - Adjusted gross profit was $2,015 million, down from $2,189 million in the prior year, with an adjusted gross margin contraction of 200 basis points to 32.3% [7] Segment Performance - North America: Net sales of $4,641 million declined 3.8% year over year, with organic sales also down 3.8% [9] - International Developed Markets: Net sales of $895 million increased 1.6% year over year, but organic sales fell 1.4% [9] - Emerging Markets: Net sales rose 3.8% year over year to $701 million, with organic sales growing 4.7% [11] Future Outlook - The company updated its full-year 2025 outlook, expecting organic net sales to decline by 3% to 3.5%, reflecting market softness [14] - Adjusted operating income is projected to fall by 10% to 12%, with an adjusted gross profit margin decline of approximately 100 basis points [15] - Adjusted EPS is forecasted in the range of $2.50 to $2.57, down from the previous outlook [15]

Core Viewpoint - Corteva plans to separate into two independent, publicly traded companies: New Corteva (Crop Protection) and SpinCo (Seed) to enhance focus and growth opportunities for both segments [2][3][4] Company Overview - Corteva has established itself as a leader in the agriculture technology sector, focusing on innovation and operational excellence [4][6] - The separation aims to create two distinct market leaders, each with tailored capital allocation strategies and growth priorities [3][5] Strategic Rationale - The separation is seen as a logical step to maximize long-term value creation by allowing each business to focus on its own market dynamics and growth strategies [5][7] - New Corteva will emphasize differentiated, innovative solutions, particularly in the biologicals segment, which is the fastest-growing market area [6][8] Financial Projections - Estimated net sales for New Corteva in 2025 are projected to be $7.8 billion, accounting for 44% of Corteva's total net sales [6][10] - SpinCo is expected to generate $9.9 billion in net sales in 2025, representing 56% of Corteva's total net sales [10][17] Transaction Details - The separation is expected to be completed in the second half of 2026 and is intended to qualify as a tax-free transaction for U.S. federal tax purposes [6][10][11] - The transaction is subject to various conditions, including board approval and legal opinions regarding its tax-free nature [11] Leadership and Management - Current Corteva Chair Greg Page will lead New Corteva, while CEO Chuck Magro will head SpinCo, with full management teams to be announced later [3][4]

Financial Data and Key Metrics Changes - Teleflex reported Q1 2025 revenues of $700.7 million, a 5% decrease year over year on a GAAP basis, and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [6][24] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [6][24] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [22] - Adjusted operating margin was 24.7%, a 190 basis point decline year over year [22] Business Line Data and Key Metrics Changes - **Americas**: Revenues were $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift service [7] - **EMEA**: Revenues decreased 2.8% year over year to $151.2 million, with strong performance in Surgical and Vascular Access offset by anesthesia [8] - **Asia**: Revenues were $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement impacts [8] - **Vascular Access**: Revenue increased 1.9% year over year to $182.4 million, driven by growth in PICCs [9] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by strong demand for intra-aortic balloon pumps [10] - **Anesthesia**: Revenue decreased 8.6% year over year to $86.6 million, with growth in endotracheal tubes offset by declines in military orders [11] - **Surgical**: Revenue increased 2% year over year to $105.8 million, with solid underlying trends [11] - **Interventional Urology**: Revenue decreased 10.7% year over year to $71 million, with strong growth in BarriGel but pressure on UroLift [12] - **OEM**: Revenue decreased 26.8% year over year to $63.9 million, impacted by a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [6] - The China business is expected to see sequential quarterly revenue improvement through the remainder of 2025 [9] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [17][18] - The acquisition of BioTronix Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [19][20] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter evolved largely as expected, with specific headwinds anticipated to be transitory [33] - The company expects 2025 adjusted constant currency revenue growth of 1% to 2%, with an updated guidance range for reported revenue growth [26] - Tariffs are expected to impact 2025 results, with an estimated $55 million headwind, primarily associated with China and Mexico [28][29] Other Important Information - The company is actively exploring strategies to mitigate tariff exposure, including optimizing the supply chain and increasing the mix of USMCA compliant products [29][30] - The company has implemented thoughtful spending controls to offset tariff impacts [53] Q&A Session Summary Question: Has there been any incremental demand on the OEM side due to supply chain issues? - Management noted a pickup in demand within the OEM business, indicating base demand rather than supply chain issues [41] Question: Can you provide more details on the $55 million tariff impact and mitigation strategies? - Management explained that the $55 million is based on current tariffs and does not include mitigation strategies, which are being explored [46][52] Question: What is the interest level in NewCo, and is there a preference for a sale versus a spin? - Management indicated significant interest in NewCo, with a parallel process for both spin and sale being pursued [59][64] Question: How does the tariff impact split between RemainCo and SpinCo? - Management stated that the impact of tariffs will affect both entities, but specifics will be discussed closer to the separation date [81] Question: What are the early views on cost and revenue synergies from the BioTronix acquisition? - Management highlighted the opportunity to leverage BioTronix's channel in Europe and Teleflex's channel in the Americas for revenue growth [84]

Financial Data and Key Metrics Changes - Teleflex reported revenues of $700.7 million for Q1 2025, a decrease of 5% year over year on a GAAP basis and a decline of 3.8% on an adjusted constant currency basis, which was within the guidance range of -3% to -4% [5][6] - Adjusted earnings per share (EPS) for the first quarter was $2.91, reflecting a 9.3% decrease year over year [5][26] - Adjusted gross margin was 60.4%, a 70 basis point decrease compared to the prior year, primarily due to cost inflation and unfavorable product mix [23] - Adjusted operating margin was 24.7%, a decline of 190 basis points year over year [23] Business Line Data and Key Metrics Changes - **Americas Revenues**: $475.7 million, a 3.2% decrease year over year, impacted by OEM declines and challenges in the UroLift office site [6] - **EMEA Revenues**: $151.2 million, down 2.8% year over year, with strong performance in Surgical and Vascular Access offset by anesthesia [7] - **Asia Revenues**: $73.8 million, a 9.7% decrease year over year, in line with expectations due to volume-based procurement in China [7][8] - **Vascular Access**: Revenue increased 1.9% year over year to $182.4 million, driven by growth in PICCs [8] - **Interventional**: Revenue was $137.5 million, an increase of 3.2% year over year, led by growth in complex catheters [9] - **Anesthesia**: Revenue decreased 8.6% year over year to $86.6 million, with growth in endotracheal tubes offset by tough comps [11] - **Surgical**: Revenue increased 2% year over year to $105.8 million, with solid underlying trends [12] - **OEM Revenue**: Decreased 26.8% year over year to $63.9 million, impacted by a lost customer contract [12] Market Data and Key Metrics Changes - The company experienced softness in orders in EMEA during Q1, which has since recovered in April [5] - The China business is expected to see sequential quarterly revenue improvement through the remainder of 2025 [8] Company Strategy and Development Direction - Teleflex announced plans to separate into two independent publicly traded companies to enhance shareholder value, with significant inbound interest in acquiring NewCo [18][19] - The acquisition of BioTronix Vascular Intervention business is on track to close by the end of Q3 2025, expected to enhance Teleflex's portfolio in the cath lab [20][21] Management's Comments on Operating Environment and Future Outlook - Management noted that the first quarter evolved largely as expected, with specific headwinds anticipated to be transitory [35] - The company expects to return to growth and create shareholder value despite current challenges, including tariffs and customer contract losses [35][36] - Adjusted EPS guidance for 2025 has been revised to a range of $13.2 to $13.6, reflecting headwinds from tariffs and other factors [31] Other Important Information - The company is actively exploring strategies to mitigate tariff exposure, including optimizing the supply chain and increasing the mix of USMCA compliant products [31][32] - The total addressable global market for treating coronary vessel perforation is estimated to exceed $80 million, highlighting growth opportunities in the vascular intervention space [21] Q&A Session Summary Question: Has there been any incremental demand on the OEM side of the business? - Management noted a pickup in demand within the OEM business, with order rates improving as the quarter progressed [43][44] Question: Can you provide more details on the $55 million tariff impact? - The $55 million figure reflects current tariffs and does not include mitigation strategies. Management is exploring various strategies to mitigate the impact [48][52] Question: Is there significant interest in NewCo? - There is a healthy mix of interest from both strategic and private equity firms, with a focus on maximizing shareholder value [73][87] Question: How is the interventional urology business performing? - The interventional urology business is performing in line with expectations, with strong growth in the Palette product [100][101]